Buparlisib in combination with tamoxifen in pretreated patients with hormone receptor-positive, HER2-negative advanced breast cancer molecularly stratified for PIK3CA mutations and loss of PTEN expression.

Welt, A., Wiesweg, M., Theurer, S., Abenhardt, W., Groschek, M., Müller, L., Schröder, J., Tewes, M., Chiabudini, M., Potthoff, K., Bankfalvi, A., Marschner, N., Schuler, M., Breitenbücher, F., 2020.

Cancer Med 9, 4527-4539. https://doi.org/10.1002/cam4.3092